📊 BDPT Key Takeaways
Is Bioadaptives, Inc.. (BDPT) a Good Investment?
BioAdaptives is a pre-revenue pharmaceutical company in severe financial distress with collapsing revenue (-55.6% YoY), massive operating losses, and negative stockholders' equity of -$1.5M indicating technical insolvency. The company faces immediate existential risk with critically low liquidity (0.07x current ratio), negative free cash flow of -$378.2K, and insufficient cash reserves to sustain operations beyond the near term.
BIOADAPTIVES, INC. shows extremely weak fundamentals, with negligible revenue, severe operating and net losses, negative free cash flow, and a deeply impaired balance sheet. While gross margin is positive, the business lacks scale and is burning cash far faster than it generates revenue, while negative equity and very weak liquidity raise substantial going-concern and financing risk.
Why Buy Bioadaptives, Inc.. Stock? BDPT Key Strengths
- Positive gross margin of 62.6% on limited revenue indicates potential product economics
- Minimal capital expenditure of $18.0K suggests lean operational structure
- Recent insider trading activity (3 Form 4 filings) shows some stakeholder engagement
- Positive gross profit and 62.6% gross margin indicate the product is not loss-making at the gross level
- Liabilities include only modest long-term debt relative to total liabilities, limiting pure term-debt burden
- Cash remains on hand, providing limited near-term operating flexibility
BDPT Stock Risks: Bioadaptives, Inc.. Investment Risks
- Negative stockholders' equity of -$1.5M represents technical insolvency and balance sheet bankruptcy
- Critical liquidity crisis with current ratio of 0.07x and only $59.3K cash against $1.6M liabilities
- Severe revenue decline of 55.6% YoY with operating losses of -$794.1K indicating inability to commercialize or sustain operations
- Negative free cash flow of -$378.2K with no clear path to profitability or cash generation
- Long-term debt of $75.7K against minimal equity and shrinking cash reserves
- Revenue declined 55.6% year over year, indicating weak demand or unstable commercialization
- Operating margin of -10114.1% and free cash flow of -$378.20K show an unsustainable cost structure versus business scale
- Negative stockholders equity of -$1.47M and a current ratio of 0.07x signal severe financial distress and recapitalization risk
Key Metrics to Watch
- Monthly cash burn rate and runway to insolvency
- Revenue stabilization or achievement of material revenue growth
- Balance sheet restructuring or capital infusion to restore positive equity
- Operating expense reduction or achievement of operating profitability
- Quarterly revenue growth and whether sales scale beyond current immaterial levels
- Operating cash burn and liquidity metrics, especially cash balance and current ratio
Bioadaptives, Inc.. (BDPT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BDPT Profit Margin, ROE & Profitability Analysis
BDPT vs Healthcare Sector: How Bioadaptives, Inc.. Compares
How Bioadaptives, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bioadaptives, Inc.. Stock Overvalued? BDPT Valuation Analysis 2026
Based on fundamental analysis, Bioadaptives, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bioadaptives, Inc.. Balance Sheet: BDPT Debt, Cash & Liquidity
BDPT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bioadaptives, Inc..'s revenue has remained relatively flat over the 5-year period, with a 8% decline. The most recent EPS of $-0.11 indicates the company is currently unprofitable.
BDPT Revenue Growth, EPS Growth & YoY Performance
BDPT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$37.6K | $0.00 |
| Q2 2025 | $675 | -$157.9K | $0.02 |
| Q1 2025 | N/A | -$197.1K | $-0.02 |
| Q3 2024 | N/A | -$13.1K | N/A |
| Q2 2024 | $675 | -$143.9K | N/A |
| Q1 2024 | $3.4K | -$287.2K | N/A |
| Q3 2023 | $3.3K | -$13.1K | N/A |
| Q2 2023 | $2.3K | -$143.9K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bioadaptives, Inc.. Dividends, Buybacks & Capital Allocation
BDPT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bioadaptives, Inc.. (CIK: 0001575142)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BDPT
What is the AI rating for BDPT?
Bioadaptives, Inc.. (BDPT) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BDPT's key strengths?
Claude: Positive gross margin of 62.6% on limited revenue indicates potential product economics. Minimal capital expenditure of $18.0K suggests lean operational structure. ChatGPT: Positive gross profit and 62.6% gross margin indicate the product is not loss-making at the gross level. Liabilities include only modest long-term debt relative to total liabilities, limiting pure term-debt burden.
What are the risks of investing in BDPT?
Claude: Negative stockholders' equity of -$1.5M represents technical insolvency and balance sheet bankruptcy. Critical liquidity crisis with current ratio of 0.07x and only $59.3K cash against $1.6M liabilities. ChatGPT: Revenue declined 55.6% year over year, indicating weak demand or unstable commercialization. Operating margin of -10114.1% and free cash flow of -$378.20K show an unsustainable cost structure versus business scale.
What is BDPT's revenue and growth?
Bioadaptives, Inc.. reported revenue of $7.9K.
Does BDPT pay dividends?
Bioadaptives, Inc.. does not currently pay dividends.
Where can I find BDPT SEC filings?
Official SEC filings for Bioadaptives, Inc.. (CIK: 0001575142) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BDPT's EPS?
Bioadaptives, Inc.. has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BDPT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bioadaptives, Inc.. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BDPT stock overvalued or undervalued?
Valuation metrics for BDPT: ROE of N/A (sector avg: 15%), net margin of -9,356.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BDPT stock in 2026?
Our dual AI analysis gives Bioadaptives, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BDPT's free cash flow?
Bioadaptives, Inc..'s operating cash flow is $-360.2K, with capital expenditures of $18.0K. FCF margin is -4,817.2%.
How does BDPT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9,356.2% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.07 (avg: 2).